News

Article

AJMC® in the Press, February 9, 2024

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Articles in Medriva and Becker’s Payer Issues referenced a study published in the February 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Screening for Health Literacy, Social Determinants, and Discrimination in Health Plans,” found that calling patients at the time of enrollment in a health plan could help in collecting health literacy data.

A piece by PharmExec referenced an article published by AJMC’s sister site, The Center for Biosimilars®. The article, “Why Pharmacovigilance Is Important for Biosimilars,” emphasized the need for constant pharmacovigilance among clinicians due to how many factors can affect the quality and performance of biosimilars.

Related Videos
Kimberly Westrich, MA, chief strategy officer, NPC
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
1 expert in this video
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Related Content
Pooled data demonstrated elinzanetant's efficacy overall and across BMI and smoking status subgroups. | Image credit: Monkey Business - stock.adobe.com
April 17th 2025

Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status

Rose McNulty
Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Cancer detection | Image credit: lordn - stock.adobe.com
April 17th 2025

Colorectal, Pancreatic Cancer Rising in Younger Adults

Pearl Steinzor
There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in older adults, according to a new study.
Managed Care Cast Presents: Unlocking the Potential of CGM Technology
April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA
A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.
Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser
Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
CA-125 test | Image Credit: jarun011 - stock.adobe.com
April 17th 2025

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Brooke McCormick
Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo